| Literature DB >> 33852961 |
Anastasia Brooks1, Xiaowen Liang2, Yonglong Zhang3, Chun-Xia Zhao4, Michael S Roberts5, Haolu Wang2, Lei Zhang6, Darrell H G Crawford7.
Abstract
The past decade has seen many advancements in the development of three-dimensional (3D) in vitro models in pharmaceutical sciences and industry. Specifically, organoids present a self-organising, self-renewing and more physiologically relevant model than conventional two-dimensional (2D) cell cultures. Liver organoids have been developed from a variety of cell sources, including stem cells, cell lines and primary cells. They have potential for modelling patient-specific disease and establishing personalised therapeutic approaches. Additionally, liver organoids have been used to test drug efficacy and toxicity. Herein we summarise cell sources for generating liver organoids, the advantages and limitations of each cell type, as well as the application of the organoids in modelling liver diseases. We focus on the use of liver organoids as tools for drug validation and toxicity assessment.Entities:
Keywords: Drug validation; Liver organoid; Toxicity assessment
Mesh:
Year: 2021 PMID: 33852961 DOI: 10.1016/j.phrs.2021.105608
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658